Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

PURPOSE Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. PATIENTS AND METHODS Two hundred seventy patients with untreated, relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of rituximab monotherapy in weekly intervals (375 mg/m(2)). Patients achieving at least a partial response were randomly assigned to receive maintenance therapy with one infusion of rituximab every 2 months, either on a short-term schedule (four administrations) or a long-term schedule (maximum of 5 years or until disease progression or unacceptable toxicity). The primary end point was event-free survival (EFS). Progression-free survival, overall survival (OS), and toxicity were secondary end points. Comparisons between the two arms were performed using the log-rank test for survival end points. RESULTS One hundred sixty-five patients were randomly assigned to the short-term (n = 82) or long-term (n = 83) maintenance arms. Because of the low event rate, the final analysis was performed after 95 events had occurred, which was before the targeted event number of 99 had been reached. At a median follow-up period of 6.4 years, the median EFS was 3.4 years (95% CI, 2.1 to 5.3) in the short-term arm and 5.3 years (95% CI, 3.5 to not available) in the long-term arm (P = .14). Patients in the long-term arm experienced more adverse effects than did those in the short-term arm, with 76% v 50% of patients with at least one adverse event (P < .001), five versus one patient with grade 3 and 4 infections, and three versus zero patients discontinuing treatment because of unacceptable toxicity, respectively. There was no difference in OS between the two groups. CONCLUSION Long-term rituximab maintenance therapy does not improve EFS, which was the primary end point of this trial, or OS, and was associated with increased toxicity.

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

BACKGROUND Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer (mCRC) patients. We assessed whether no continuation is non-inferior to continuation of bevacizumab after completing first-line chemotherapy. PATIENTS AND METHODS In an open-label, phase III multicentre trial, patients with mCRC without disease progression after 4-6 months of standard first-line chemotherapy plus bevacizumab were randomly assigned to continuing bevacizumab at a standard dose or no treatment. CT scans were done every 6 weeks until disease progression. The primary end point was time to progression (TTP). A non-inferiority limit for hazard ratio (HR) of 0.727 was chosen to detect a difference in TTP of 6 weeks or less, with a one-sided significance level of 10% and a statistical power of 85%. RESULTS The intention-to-treat population comprised 262 patients: median follow-up was 36.7 months. The median TTP was 4.1 [95% confidence interval (CI) 3.1-5.4] months for bevacizumab continuation versus 2.9 (95% CI 2.8-3.8) months for no continuation; HR 0.74 (95% CI 0.58-0.96). Non-inferiority could not be demonstrated. The median overall survival was 25.4 months for bevacizumab continuation versus 23.8 months (HR 0.83; 95% CI 0.63-1.1; P = 0.2) for no continuation. Severe adverse events were uncommon in the bevacizumab continuation arm. Costs for bevacizumab continuation were estimated to be ∼30,000 USD per patient. CONCLUSIONS Non-inferiority could not be demonstrated for treatment holidays versus continuing bevacizumab monotheray, after 4-6 months of standard first-line chemotherapy plus bevacizumab. Based on no impact on overall survival and increased treatment costs, bevacizumab as a single agent is of no meaningful therapeutic value. More efficient treatment approaches are needed to maintain control of stabilized disease following induction therapy. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, number NCT00544700.

Tenerife South Airport (Phase III)

An architecture of light and shadows is proposed for this airport for the twenty-first century. A great concrete and stone box to frame the incredible view south towards a red mountain that rests Sphinx-like over the Atlantic. = Se propone para este aeropuerto para el siglo XXI una arquitectura construída con la luz y con las sombras. Una gran caja de hormigón que enmarca un maravilloso paisaje: el océano atlántico al sur con la montaña roja que se acuesta sobre el mar como si de una esfinge se tratara.

A study of the feasibility of utilizing solid wastes for building materials : phase III and IV summary reports /

Mode of access: Internet.

An investigation of the effectiveness of existing bridge design methodology in providing adequate structural resistance to seismic disturbances : Phase III, Nonlinear soil-structure interaction of skew highway bridges : final report : prepared for Federal Highway Administration, Offices of Research and Development /

Bibliography: p. 46-48.

Collision avoidance radar braking systems investigation - phase III study. Final report.

National Highway Traffic Safety Administration, Washington, D.C.

Methods for aquatic toxicity identification evaluations : phase III : toxicity confirmation procedures /

Mode of access: Internet.

Collision avoidance radar braking systems investigation - phase III study, technical report. Final report.

National Highway Traffic Safety Administration, Washington, D.C.

Calspan/Chrysler Research Safety Vehicle - phase III: final technical report. Volume I: executive summary.

National Highway Traffic Safety Administration, Washington, D.C.

Research Safety Vehicle - phase III: final design report. Volume II: appendices.

National Highway Traffic Safety Administration, Washington, D.C.

Performance testing and system characterization. DOE Hybrid Test Vehicle phase III: final report.

Energy Department, Washington, D.C.

An overview of roadway delineation research. Phase III. Final report.

Federal Highway Administration, Washington, D.C.

Statewide pedestrian study. Phase III report: correlation and evaluation of pedestrian accident data. Final report.

Mode of access: Internet.

Construction of a comprehensive causal network, phase III: final report (volume I).

National Highway Traffic Safety Administration, Washington, D.C.

A manual of model police traffic services: policies, procedures, rules. Phase III - model police traffic services rules.

National Highway Traffic Safety Administration, Washington, D.C.